Table 2.
Treatment characteristics
| Authors | Diagnostics | Parasitaemia | Drug | Dosing (total) | Period | Adverse events | Mean FCT (h) | Mean PCT (h) | Cure | Last day of observation |
|---|---|---|---|---|---|---|---|---|---|---|
| Siswantoro et al. | MIC + PCR | 645 p/µl | Chloroquine | 25 mg/kg (+150 mg base) | Over 3 days | – | 24 | 48 | Y~ | 28 |
| Same-Ekobo et al. | MIC | 534,642 p/µl (total) | Artesunate | 600 mg | Over 5 days | Vertigo, non-severe transient decrease of reticulocytes in 1 participant | 36.6 | 38.8 | Y | 14 |
| Ringwald et al. | MIC | 2250–40,680 p/µl | Pyronaridine | 32 mg/kg | Over 3 days | Mild gastrointestinal disturbances, pruritus | 45 | 57 | Y | 14 |
| MIC | 6656–13,680 p/µl | Chloroquine | 25 mg/kg | Over 3 days | – | 24 | 60 | Y | 14 | |
| Radloff et al. | MIC | 700–5000 p/µl | Atovaquone/proguanil | 3000 mg/1200 mg | Over 3 days | – | – | 72–168 | Y | 28 |
| Danis et al. | – | – | Mefloquine | 0.5–1.25 mg | Once and twice | – | – | 72–120 | Y | – |
MIC microscopy, PCR polymerase chain reaction, Y yes, –not mentioned in the original publication, ~ adequate clinical and parasitological response of P. ovale at day 28, however, reappearing P. vivax in follow up period at days 14 and 23